Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If we get firm news no bk or a not as bad quarterly report 30/40m mkt cap easy.
Ebhi .405x.415 :))
Somone told me wrap the fish in foil.Did you ever do fish that way?
Bizzy is good.:)))
Thanks,Getting close today.Would like to break and hold above 50 rsi.Tried twice recently only to turn back.
Ebhi,Pretty good volume hittin the ask today.
Gotta get one of those.How long do you do them?When I cover a pan with foil(holes on top)it only takes 10 minutes and they get really soft.Crappy weather yesterday so didn't grill.I am looking for a quick and easy Salmon recipe.Thanks Bob :))
Real music~
You will get it~
Rules to live by.~
Yea its early~Zevon~Werewolves~
The End~AC/DC~
Gunners~
Janice told me about this board.Lets grill.Through those veggies in a foil pan and grillem up 10 minutes.Thats it.Crazy Bob~
Thanks Enjoy our short Summer ~
On its way.eom
REO~Time for me to Fly~
Hook me up with phils site.I grill everything from here on out.Trying fish this year.Salmon is a interest to me.Thanks Bob :))
Nah~Rainbow~Stone Cold~
We need a Grillin board.Need a good Salmon grillin recipe.I am a big griller from now till the fall.Bob :)))
Rossington Collins Band~"Dont't misunderstand me"
Pure Praire league~Aime~
Good read:A Cold Call, a Blog, and a $20 Million Lawsuit
By JESS MCCUAN, INC.COM
Filed Under: Small Business, Online Business
A North Carolina entrepreneur blogs a warning to her industry -- and gets sued for her troubles.
In January, Leslie Richard got a call from a man from Vision Media Television. The Boca Raton, Florida, TV production company wanted to know if Richard would agree to be interviewed for a documentary on eco-fashion. According to Richard, the caller implied that the film might air on PBS or possibly on CNN.
"I was nervous, but I was totally, like, Yeah -- I'll do it," says Richard. A TV appearance promised to be a huge PR boost for her two-year-old Asheville, North Carolina, company, The Oko Box, which sells clothing made of organic cotton, hemp, and bamboo.
More from Inc.com11 Ways to Land Media Coverage
11 Ways to Improve Your Website
Top 10 Industries to Start and Grow a Business
As talks progressed, however, Richard, 31, grew increasingly skeptical about the documentary. She says another Vision Media employee told her that Oko Box would be charged $22,900 to cover some production expenses, plus $3,000 for travel costs. Feeling "creeped out," Richard called the Better Business Bureau and posted a message about her experience on her company's blog. "Look alive small eco business owners," she wrote, " 'cause there is a new scam targeting us. sing television lingo, an entire team of people, a website, video footage, and [a] whole bag of lies to cover their scheme."
As cathartic as this blog post may have been, it put Richard's business at risk. Anything posted on a CEO's blog -- including reader comments -- can be construed as carrying the weight of a company's endorsement, says Marc Zwillinger, an attorney in the Washington, D.C., office of Sonnenschein Nath & Rosenthal. "Blogging is a cheap and scalable way to talk to interested people," adds Seth Godin, an avid blogger and the author of 10 books on marketing. "But understand that while you advocate for your company, you are also walking a tightrope from a legal and business point of view."
Initially, Richard says, her blog elicited responses from more than 50 business owners who said they had dealt with Vision Media and shared her concerns. One person sent Richard a statement found on PBS's website from 2004 that said the network was "not associated with and does not endorse" a list of companies that included Vision Media. When the production company threatened to sue Richard if she didn't take down her blog, she wrote: "Um, yeah VMT your scam is being posted & has already been reported, and your imaginary lawyers can't do anything about it."
In July, Vision Media made good on its threat and filed a lawsuit in Florida against Richard and her company, asserting that the comments on Oko Box's blog (which Richard reposted in a members-only chat room maintained by a group for social entrepreneurs) had directly resulted in $5 million in lost business. The suit also asked the court to award Vision Media $15 million in punitive damages.
Mark Miller, an executive producer at Vision Media, denies that his company claimed to work with PBS. He also says Vision Media has a good rating with the Better Business Bureau, contrary to a post published in the comments section of Richard's website. "We've lost a lot of business as a result of her blog," Miller says.
After the initial shock wore off, Richard found a lawyer in Florida who was willing to work with her pro bono. At presstime in late September, Richard was close to a settlement with Vision Media, and she said she was prepared to take down the blog posts.
Richard says the nine-month standoff could have been avoided if Vision Media had just said, "We're a video company that does advertorials; you can use it however you want, and this is how much it costs." Miller asserts that his company does, as a policy, mention fees in the first phone call and that Richard misunderstood the pitch. "Our presentation is crystal clear," he says. (PBS declined to elaborate on its statement concerning Vision Media.)
As CEO blogs proliferate, so will the legal issues. "My sense is that she could have written her warning post in a more careful way," Godin says. "I want to push CEOs to be authentic on their blogs and to be selfless in trying to help readers. But they also have to understand that their words will be out there and widely seen. So they owe it to their stakeholders to act responsibly
Thanks learning.eom Bob :))
We shall see.Every one of my retailers/developers worked out well off my bottom posts on ihub.Ebhi is the only one that the market seems to need a little more verification.From my dd,I think the q gives them that nudge we need.We can't believe cbl passed pei.Doubles/triples in the last two months in pei/cbl.Psun did a double also.Ddr/grt/bont doing well.I don't want to talk about pir as I missed the run from .10.Twb and tlb are two more too watch.Bob :))
A little decent news and we get a pir/psun/bont reaction just as they had off the bottom.
Bottom line here is BK or no BK.I am in the no bk camp.The street does not care if earnings beat or even come close these days.What they do want to see is some sort of improvement.My opinion is ebhi will see a bottom line improvement.I believe the higher salaried cuts~Third party sales(Amazon)~Actual follow through sales from their company site(Top 10 in the industry as per my previous post)~Aggressive 1st q sales(started in January)and general operations cuts will help 1st q report.Then we have the debt re-negotiated with the holders and two of "their people" placed on the board.Do the dd.Pick your poison.lol Bob :))PS:Hope you took a looky at the list I gave you of retailers and developers(smokin).A hint of "We will survive" and we run like psun/pir/bont off these lows.
Hey Biggie,Bont bustin a move along with psun~twb and tlb.Crazy retailers.Mall developers cbl~pei~ddr nad grt strong also.Little Eddie still trying to get out of its own way.lol Bob :))
Top 10 Online Retailers by Conversion Rate: March 2009
By Bryan EisenbergApril 24th, 2009
Here are the top 10 converting websites for March 2009*. These are based on Nielson Panel data and are calculated by toolbar user to final conversion. Conversion-rate data is based on visitor conversion rates, not session conversion rates: i.e., No. of unique customers/No. of unique visitors.
1. Schwan’s 50.5
2. FTD 27.2
3. ProFlowers 24.3
4. Vitacost.com 23.7
5. Woman Within 22.7
6. Roaman’s 21.1
7. ColdWater Creek 20.0
8. Eddie Bauer 19.3
9. Blair.com 20.20
10. QVC 17.30
*Source: Nielsen Online
Wild west:Dendreon's Prostate Vaccine Validated with Drama
Test results confirm Provenge extends survival for last-stage patients, yet the company's stock briefly plummeted before trading was halted
By Catherine Arnst
linkedin connections Dendreon (DNDN) appears to have defied the many skeptics of its controversial experimental prostate cancer vaccine, Provenge. The drug extended survival in patients in the last stages of the disease by a median of 4.1 months, according to a the results of a clinical trial presented on Apr. 28—a month longer than Taxotere, a harsh chemotherapy that is currently the only drug for advanced prostate cancer.
The study of 512 men also found that 31.7% of the patients on Provenge were still alive at the three-year mark, compared with 23% of those on a placebo. Side effects from Provenge were minimal, although four men did develop non-fatal blood clots.
Although far from a cure, the drug represents the first significant progress in more than a decade against advanced prostate cancer, which kills some 30,000 men in the U.S. each year. For very sick patients, any additional survival time is considered a breakthrough by cancer specialists; the 4.1 months of added survival time represent a median, meaning that half the patients on the drug lived longer than four months and the other half lived less. As such, Provenge has won praise from doctors and patients alike. "Hundreds of thousands of men fighting prostate cancer will now have real hope that a safe and effective new option will be available to them in their fight for life," said Scott Riccio, executive director of the cancer patient advocacy group Accelerate Progress.
Dendreon's stock, however, suffered a nasty and unexplained blow in a couple of minutes before trading was halted on the Nasdaq exchange ahead of the announcement of the trial results. Between 1:25 p.m. and 1:27 p.m., the stock price fell 69%, to 11.81, at which point trading was stopped. The Nasdaq initially thought a broker's error was to blame for the drop, but later announced the stock trades would stand, according to Bloomberg. Nasdaq officials would not say when trading in Dendreon would reopen.
first cancer vaccine to extend life
The stock slide was a marked reversal of what happened earlier this month, when Dendreon shares tripled in value on Apr. 14 after initial reports of the successful trial were announced. Short sellers had bet heavily against Dendreon.
Provenge is the first cancer vaccine to prove in a clinical trial that it can keep patients alive longer. For decades, scientists have been trying to develop such a vaccine, meant to activate the body's own immune system to attack tumors, with little success. The Provenge trial "validates the long-standing but elusive aspiration to harness a patient's own immune system to fight cancer," said Dr. Philip Kantoff, head of the prostate cancer program at Dana-Farber Cancer Institute in Boston and a principal investigator of the trial.
Dendreon couldn't help but gloat a little over the results, released almost exactly two years after the Food & Drug Administration, in a much-debated decision, rejected the company's application for Provenge.
A panel of experts convened by the FDA had voted 17 to 2 to approve the drug, despite inconclusive evidence that it was effective. But the FDA rejected their recommendation, leading to a fire storm of protest from prostate cancer patients and Dendreon investors. The company set off on a larger trial designed to prove that the drug could extend survival.
FDA reapplication later this year
Ever since Gold announced two weeks ago that results met FDA requirements, the Seattle-based company has displayed a huge banner on the entire front of its headquarters that says: "Congratulations Dendreon. Global Impact Starts Here." And in releasing the full results Tuesday at the American Urological Association meeting in Chicago, Gold said they "confirm the potential for Provenge in prostate cancer and validate the potential of our pipeline."
Gold has said the company will reapply for FDA approval by the end of this year.
Experts say he has reason to be confident of approval, since Provenge seems to be both safe and more effective than Taxotere. The Provenge results are considered statistically significant because the trial had a so-called "p-value" of 1.0032—meaning the odds were less than 3.2% that the outcome resulted from chance. The FDA traditionally will not consider a drug with a p-value of more than 5%.
The FDA is expected to closely monitor Provenge's complex manufacturing process, however. The drug must be customized to each patient: Blood cells are collected from the patient and mixed with a protein found on prostate cancer cells and a vector designed to stimulate the immune system. The resulting drug is given as a one-time treatment, delivered by infusion three times over two weeks. Ideally it will alert the immune system to attack the prostate tumor while leaving healthy tissue alone.
That process probably guarantees the drug will be costly, though the company has not disclosed pricing details. If the drug is approved, analysts expect it will bring in more than $1 billion in annual revenues within a few years.
Well ebhi couldn't break the 50 rsi on its second try this month yesterday.Maybe 3rd time will be the charm.Bob :))
HeHe,Play the beaten down nyse/nasdaq companies.Fully reporting and much more predictable.
Thank You for being a friend~
Keep waiting for the BIG signed contracts and Actual share structure.Been posting the same thing for months now.If eeso wants real money flowing into the stock then just do what I said.Buyout is not a excuse and the share price shows that as a fact.Bob
Exactly my friend.Have a great rest of the weekend.I have been busy with my biz.I had to post the info while it was fresh in my mind.I read other pump/basher boards and 95% of what I see is pure lies backed up by nothing in regards to bk.Bob :))
Good Evening Joe,I did a little sector analysis yesterday.I compared ebhi to some others in the sector that were either havibg a really hard time or faced/facing bk.Pir low was .10 and is now trading at 1.90.Bont low was .76 and is now trading at 2.21.Twb low was 1.01 and is now trading at 2.42.Tlb low was 1.19 and is now trading at 2.30.Lastly is psun where the low was .72 and is now at 3.14.I targeted these companies because of their troubles and somewhat similar shares out.The market cap for these companies is as folloes.Pir~170 mill~Bont~39 mill~Tlb~123 mill~Twb~60 mill and psun~206 mill.With that being said.The industry average is 214 mill.Now ebhi has a 12 mill market cap.With all the cost cutting(read news from late Jan.on).The aggressive sales approach after the holidays and Pay cuts/reductions of staff the bottom line should even start to look better for Q1.I think a 30/50 low end market cap is warranted now(So does Firebrand imo).Then we see the q1 report.Our revenue/Gross margin and Ebitda is right in line with the industry averages.Food for thought.Bob :))PS:Almost forgot one thing.The charts look great.lol
Agree,Also a flower garden should be similar to a vegetable garden in a dedicated area.
What is a Garden?I have always considered a garden where you plant vegetables.Then I hear people refer to their garden as the work they do in their yard aka I am doing work in the garden.Its their yard and they have no vegetables or a actual area dedicated to flowers.Just one of those crazy thoughts running through my mind.lol Bob :))
Same here and watching my Pats load up on defense.I worked all day till 7.I have friends that had Draft parties.You should see them when the actual games are being played.lol Bob :))
Golden Girls' star Bea Arthur dies at 86
By LYNN ELBER – 1 hour ago
LOS ANGELES (AP) — Beatrice Arthur, the tall, deep-voiced actress whose razor-sharp delivery of comedy lines made her a TV star in the hit shows "Maude" and "The Golden Girls" and who won a Tony Award for the musical "Mame," died Saturday. She was 86.
Arthur died peacefully at her Los Angeles home with her family at her side, family spokesman Dan Watt said. She had cancer, Watt said, declining to give details.
"She was a brilliant and witty woman," said Watt, who was Arthur's personal assistant for six years. "Bea will always have a special place in my heart."
Arthur first appeared in the landmark comedy series "All in the Family" as Edith Bunker's outspoken, liberal cousin, Maude Finley. She proved a perfect foil for blue-collar bigot Archie Bunker (Carroll O'Connor), and their blistering exchanges were so entertaining that producer Norman Lear fashioned Arthur's own series.
In a 2008 interview with The Associated Press, Arthur said she was lucky to be discovered by TV after a long stage career, recalling with bemusement CBS executives asking about the new "girl."
"I was already 50 years old. I had done so much off-Broadway, on Broadway, but they said, `Who is that girl? Let's give her her own series,'" Arthur said.
"Maude" scored with television viewers immediately on its CBS debut in September 1972, and Arthur won an Emmy Award for the role in 1977.
The comedy flowed from Maude's efforts to cast off the traditional restraints that women faced, but the series often had a serious base. Her husband Walter (Bill Macy) became an alcoholic, and she underwent an abortion, which drew a torrent of viewer protests. Maude became a standard bearer for the growing feminist movement in America.
"She was an incredible actress and a woman I will miss, and I think everyone else will," said Bud Yorkin, producer of "Maude" with partner Lear.
The ratings of "Maude" in the early years approached those of its parent, "All in the Family," but by 1977 the audience started to dwindle. A major format change was planned, but in early 1978 Arthur announced she was quitting the show.
"It's been absolutely glorious; I've loved every minute of it," she said. "But it's been six years, and I think it's time to leave."
"Golden Girls" (1985-1992) was another groundbreaking comedy, finding surprising success in a television market increasingly skewed toward a younger, product-buying audience.
The series concerned three retirees — Arthur, Betty White and Rue McClanahan — and the mother of Arthur's character, Estelle Getty, who lived together in a Miami apartment. In contrast to the violent "Miami Vice," the comedy was nicknamed "Miami Nice."
As Dorothy Zbornak, Arthur seemed as caustic and domineering as Maude. She was unconcerned about the similarity of the two roles. "Look — I'm 5-feet-9, I have a deep voice and I have a way with a line," she told an interviewer. "What can I do about it? I can't stay home waiting for something different. I think it's a total waste of energy worrying about typecasting."
The interplay among the four women and their relations with men fueled the comedy, and the show amassed a big audience and 10 Emmys, including two as best comedy series and individual awards for each of the stars.
McClanahan said Arthur felt constrained by the show during its later years and in 1992 she announced she was leaving "Golden Girls."
"Bea liked to be the star of the show, she didn't really like to do that ensemble playing," McClanahan said.
McClanahan first worked with Arthur on "Maude," playing her best friend, Vivian. The women quickly became close friends in real life. McClanahan recalled Arthur as a kind and caring person with a no-nonsense edge.
The three other stars returned in "The Golden Palace," but it lasted only one season.
Arthur was born Bernice Frankel in New York City in 1922. When she was 11, her family moved to Cambridge, Md., where her father opened a clothing store. At 12 she had grown to full height, and she dreamed of being a petite blond movie star like June Allyson. There was one advantage of being tall and deep-voiced: She was chosen for the male roles in school plays.
Bernice — she hated the name and adopted her mother's nickname of Bea — overcame shyness about her size by winning over her classmates with wisecracks. She was elected the wittiest girl in her class. After two years at a junior college in Virginia, she earned a degree as a medical lab technician, but she "loathed" doing lab work at a hospital.
Acting held more appeal, and she enrolled in a drama course at the New School of Social Research in New York City. To support herself, she sang in a night spot that required her to push drinks on customers.
During this time she had a brief marriage that provided her stage name of Beatrice Arthur. In 1950, she married again, to Broadway actor and future Tony-winning director Gene Saks.
After a few years in off-Broadway and stock company plays and television dramas, Arthur's career gathered momentum with her role as Lucy Brown in the 1955 production of "The Threepenny Opera."
In 2008, when Arthur was inducted in the TV Academy Hall of Fame, Arthur pointed to the role as the highlight of her long career.
"A lot of that had to do with the fact that I felt, `Ah, yes, I belong here,'" Arthur said.
More plays and musicals followed, and she also sang in nightclubs and played small roles in TV comedy shows.
Then, in 1964, Harold Prince cast her as Yente the Matchmaker in the original company of "Fiddler on the Roof."
Arthur's biggest Broadway triumph came in 1966 as Vera Charles, Angela Lansbury's acerbic friend in the musical "Mame," directed by Saks. Richard Watts of the New York Post called her performance "a portrait in acid of a savagely witty, cynical and serpent-tongued woman."
She won the Tony as best supporting actress and repeated the role in the unsuccessful film version that also was directed by Saks, starring Lucille Ball as Mame. Arthur would play a variation of Vera Charles in "Maude" and "The Golden Girls."
"There was no one else like Bea," said "Mame" composer Jerry Herman. "She would make us laugh during `Mame' rehearsals with a look or with a word. She didn't need dialogue. I don't know if I can say that about any other person I ever worked with."
In 1983, Arthur attempted another series, "Amanda's," an Americanized version of John Cleese's hilarious "Fawlty Towers." She was cast as owner of a small seaside hotel with a staff of eccentrics. It lasted a mere nine episodes.
Between series, Arthur remained active in films and theater. Among the movies: "That Kind of Woman" (1959), "Lovers and Other Strangers" (1970), Mel Brooks' "The History of the World: Part I" (1981), "For Better or Worse" (1995).
The plays included Woody Allen's "The Floating Light Bulb" and "The Bermuda Avenue Triangle," written by and costarring Renee Taylor and Joseph Bologna. During 2001 and 2002 she toured the country in a one-woman show of songs and stories, "... And Then There's Bea."
Arthur and Saks divorced in 1978 after 28 years. They had two sons, Matthew and Daniel. In his long career, Saks won Tonys for "I Love My Wife," "Brighton Beach Memoirs" and "Biloxi Blues." One of his Tony nominations was for "Mame."
In 1999, Arthur told an interviewer of the three influences in her career: "Sid Caesar taught me the outrageous; (method acting guru) Lee Strasberg taught me what I call reality; and ('Threepenny Opera' star) Lotte Lenya, whom I adored, taught me economy."
In recent years, Arthur made guest appearances on shows including "Curb Your Enthusiasm" and "Malcolm in the Middle." She was chairwoman of the Art Attack Foundation, a non-profit performing arts scholarship organization.
Arthur is survived by her sons and two granddaughters. No funeral services are planned.